JP6261617B2 - 嚢胞性腎疾患の処置に使用されるリンパ管新生を誘発する作用物質 - Google Patents

嚢胞性腎疾患の処置に使用されるリンパ管新生を誘発する作用物質 Download PDF

Info

Publication number
JP6261617B2
JP6261617B2 JP2015557515A JP2015557515A JP6261617B2 JP 6261617 B2 JP6261617 B2 JP 6261617B2 JP 2015557515 A JP2015557515 A JP 2015557515A JP 2015557515 A JP2015557515 A JP 2015557515A JP 6261617 B2 JP6261617 B2 JP 6261617B2
Authority
JP
Japan
Prior art keywords
vegf
pharmaceutical composition
composition according
agent
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015557515A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016509018A (ja
JP2016509018A5 (enExample
Inventor
ロング，デイビッド
ウィンヤード，ポール
ファン，ジェニファー
Original Assignee
ユーシーエル ビジネス ピーエルシー
ユーシーエル ビジネス ピーエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユーシーエル ビジネス ピーエルシー, ユーシーエル ビジネス ピーエルシー filed Critical ユーシーエル ビジネス ピーエルシー
Publication of JP2016509018A publication Critical patent/JP2016509018A/ja
Publication of JP2016509018A5 publication Critical patent/JP2016509018A5/ja
Application granted granted Critical
Publication of JP6261617B2 publication Critical patent/JP6261617B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1783—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2015557515A 2013-02-14 2014-02-14 嚢胞性腎疾患の処置に使用されるリンパ管新生を誘発する作用物質 Expired - Fee Related JP6261617B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361764626P 2013-02-14 2013-02-14
US61/764,626 2013-02-14
PCT/GB2014/050436 WO2014125291A1 (en) 2013-02-14 2014-02-14 Agents which induce lymphangiogenesis for use in the treatment of cystic kidney disease

Publications (3)

Publication Number Publication Date
JP2016509018A JP2016509018A (ja) 2016-03-24
JP2016509018A5 JP2016509018A5 (enExample) 2017-03-16
JP6261617B2 true JP6261617B2 (ja) 2018-01-17

Family

ID=50150722

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015557515A Expired - Fee Related JP6261617B2 (ja) 2013-02-14 2014-02-14 嚢胞性腎疾患の処置に使用されるリンパ管新生を誘発する作用物質

Country Status (4)

Country Link
US (1) US20160000873A1 (enExample)
EP (1) EP2956159A1 (enExample)
JP (1) JP6261617B2 (enExample)
WO (1) WO2014125291A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019195770A1 (en) 2018-04-06 2019-10-10 Atyr Pharma, Inc. Compositions and methods comprising anti-nrp2 antibodies
TWI725499B (zh) * 2019-07-31 2021-04-21 優仕達資訊股份有限公司 用以定位行動裝置之天線系統
AU2020358854B2 (en) 2019-10-03 2026-08-13 Atyr Pharma, Inc. Compositions and methods comprising anti-NRP2 antibodies

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
ZA858044B (en) 1984-11-01 1987-05-27 American Home Prod Oral vaccines
US5166059A (en) 1987-06-16 1992-11-24 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy using gene fusions for genetic or acquired disorders
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
EP0783572B1 (en) 1994-09-22 2005-04-27 Licentia Ltd. Promoter for the receptor tyrosine kinase, tie
US6645933B1 (en) 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
US5792453A (en) 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
US20010034062A1 (en) 2000-02-09 2001-10-25 Scott Koenig Antibody gene therapy with adeno-associated viral vectors
US8007790B2 (en) * 2006-04-03 2011-08-30 Stowers Institute For Medical Research Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
US20080267924A1 (en) 2007-02-07 2008-10-30 Vegenics Limited Autologous lymph node transfer in combination with vegf-c or vegf-d growth factor therapy to treat secondary lymphedema and to improve reconstructive surgery
WO2010078624A1 (en) * 2009-01-07 2010-07-15 Vegenics Limited Materials and methods for the treatment of hypertension

Also Published As

Publication number Publication date
US20160000873A1 (en) 2016-01-07
EP2956159A1 (en) 2015-12-23
WO2014125291A1 (en) 2014-08-21
JP2016509018A (ja) 2016-03-24

Similar Documents

Publication Publication Date Title
AU2015287397B2 (en) Therapeutic use of bone morphogenetic proteins
CN101014358A (zh) 色素上皮所衍生因子的生物活性及使用方法
JP2014533235A5 (enExample)
JP7291423B2 (ja) ＡＩＭＰ２－ＤＸ２およびｍｉＲ－１４２の標的核酸を含むベクター、ならびにその使用
AU2011210825A1 (en) Pro-angiogenic fragments of prominin-1 and uses thereof
CN116507370A (zh) 使用AIMP2-DX2和任选地miR-142的靶序列及其组合物治疗神经元疾病的方法
JP2016509018A (ja) 嚢胞性腎疾患の処置に使用されるリンパ管新生を誘発する作用物質
AU782833B2 (en) Use of a recombinant defective adenovirus comprising a nucleic acid encoding an angiogenic factor for treating pulmonary hypertension
KR101438996B1 (ko) 혈관형성 촉진 활성을 갖는 돌연변이형 합토글로빈의 용도
ES2390763T3 (es) Fragmentos peptídicos del factor HARP que inhiben la angiogénesis
JP2016509018A5 (enExample)
US20050209178A1 (en) Methods and compositions for the treatment of obesity
JP2017530128A (ja) 肝細胞増殖因子及びストローマ細胞由来因子１αを用いた末梢動脈疾患の予防または治療用組成物
US7897145B2 (en) Methods for the treatment of renal failure
US12036265B2 (en) Compositions and methods relating to bone repair and regeneration
JP2014526440A (ja) 炎症誘発性状態の治療および予防のためのｈｄｌ関連分子の使用
US20260091078A1 (en) Oligopeptide that inhibits angiogenesis and vascular function
KR20220035634A (ko) AIMP2-DX2 및 miR-142의 표적 핵산을 포함하는 재조합 벡터
US9371523B2 (en) Cell migration regulator
KR101590959B1 (ko) 육량체 형성 도메인과 결합된 trail 융합 단백질 및 이를 유효성분으로 포함하는 혈관 재협착증 치료용 조성물
CA2483431A1 (en) Alternatively spliced nucleic acid molecules
US20250188141A1 (en) Decoy peptides for treating diseases or conditions modulated by interleukin-33
EP2385840A1 (en) Materials and methods for the treatment of hypertension
KR101595641B1 (ko) Cd31-itim 폴리펩타이드 또는 이를 코딩하는 유전자를 포함하는 혈관생성 촉진용 약학 조성물
CN110577589A (zh) 胰岛素样生长因子结合蛋白4突变体及其制药用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170210

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171124

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171212

R150 Certificate of patent or registration of utility model

Ref document number: 6261617

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees